<DOC>
	<DOCNO>NCT00322556</DOCNO>
	<brief_summary>The objective trial assessment safety efficacy IgPro10 patient PID , assessment tolerability high infusion rate . To demonstrate safety , number infusion temporally associate AEs , rate , severity relationship AEs vital sign change infusion evaluate .</brief_summary>
	<brief_title>Safety Efficacy Intravenous Immunoglobulin IgPro10 Patients With Primary Immunodeficiencies ( PID )</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>IgG Deficiency</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Key Patients CVID ( Common Variable Immunodeficiency ) XLA ( Xlinked agammaglobulinemia ) : Participated Phase III clinical study intravenous IgPro10 ( study number ZLB03_002CR ) 3 4 weekly interval 12 month ( refer 'old ' subject ) OR Were ≥ 6 year age , stable intravenous immunoglobulin therapy ( 200800 mg IgG per kg body weight ) 3 4week interval least 6 month , AND interest participate Phase III clinical study subcutaneous IgPro20 ( study number ZLB04_009CR ) ( refer 'new ' subject ) Written informed consent Key Diagnosis epilepsia Insulin dependent diabetes Administration steroid ( daily ≥ 0.15 mg prednisone equivalent/kg/day ) immunosuppressive drug History cardiac insufficiency ( NYHA III/IV ) , cardiomyopathy , congestive heart failure , severe hypertension</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>71 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Immunoglobulin Intravenous</keyword>
	<keyword>Agammaglobulinemia</keyword>
	<keyword>Hypogammaglobulinemia</keyword>
	<keyword>Common variable immunodeficiency</keyword>
	<keyword>Immunoglobulin G</keyword>
	<keyword>Children</keyword>
</DOC>